Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO 80206, USA.
Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO 80206, USA.
Clin Chest Med. 2023 Dec;44(4):771-783. doi: 10.1016/j.ccm.2023.06.009. Epub 2023 Aug 14.
Treatment of M avium pulmonary disease requires a three-drug, macrolide-based regimen that is administered for 12 months beyond culture conversion. The regimen can be administered 3 days a week in non-cavitary, nodular bronchiectatic disease but should be given daily when cavitary disease is present. For treatment refractory disease, amikacin liposome inhalation suspension is added to the regimen. Parenteral amikacin or streptomycin should be administered in the setting of extensive radiographic involvement or macrolide resistance. Recurrence of disease is common and often due to reinfection. Novel and repurposed agents are being evaluated in clinical trials.
治疗鸟分枝杆菌肺病需要一种三联药物、大环内酯类药物方案,在培养转换后再使用 12 个月。该方案可在非空洞性、结节性支气管扩张病变中每周使用 3 天,但在存在空洞性病变时应每天使用。对于治疗耐药疾病,可将阿米卡星脂质体吸入混悬液添加到方案中。在广泛的放射影像学受累或大环内酯类药物耐药的情况下,应给予阿米卡星或链霉素进行注射治疗。疾病复发很常见,通常是由于再感染。新的和重新定位的药物正在临床试验中进行评估。